Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., commonly referred to as Ocular Therapeutix, is a pioneering biopharmaceutical company headquartered in the United States. Founded in 2014, the company focuses on the development and commercialisation of innovative therapies for ocular diseases and conditions. With a strong presence in the ophthalmic industry, Ocular Therapeutix has made significant strides in creating unique drug delivery systems that enhance patient outcomes. The company’s flagship products include Dextenza, a sustained-release dexamethasone insert for post-surgical inflammation, and OTX-TP, a novel treatment for glaucoma. These offerings distinguish Ocular Therapeutix in the market, showcasing its commitment to advancing ocular health. Recognised for its innovative approach, Ocular Therapeutix continues to solidify its position as a leader in the ophthalmic therapeutics sector, driving forward with a robust pipeline of products aimed at addressing unmet medical needs.
DitchCarbon Score
How does Ocular Therapeutix, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ocular Therapeutix, Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ocular Therapeutix, Inc.'s reported carbon emissions
Ocular Therapeutix, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their Scope 1, 2, or 3 emissions. The absence of emissions data suggests that the company may still be in the early stages of formalising its climate commitments or reporting practices. Without specific initiatives or targets outlined, it is unclear how Ocular Therapeutix plans to address its carbon footprint or contribute to broader climate goals within the industry.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ocular Therapeutix, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
